- Previous Close
39.96 - Open
40.02 - Bid 39.72 x 300400
- Ask 39.74 x 40000
- Day's Range
39.73 - 40.08 - 52 Week Range
29.20 - 42.43 - Volume
223,709 - Avg. Volume
1,772,439 - Market Cap (intraday)
259.377B - Beta (5Y Monthly) 0.15
- PE Ratio (TTM)
20.44 - EPS (TTM)
1.95 - Earnings Date Jul 25, 2024
- Forward Dividend & Yield 1.35 (3.39%)
- Ex-Dividend Date Mar 14, 2024
- 1y Target Est
43.45
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
www.roche.com103,605
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: RHHBY
View MorePerformance Overview: RHHBY
Trailing total returns as of 9/26/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RHHBY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RHHBY
View MoreValuation Measures
Market Cap
259.38B
Enterprise Value
289.82B
Trailing P/E
20.41
Forward P/E
13.26
PEG Ratio (5yr expected)
1.25
Price/Sales (ttm)
3.58
Price/Book (mrq)
7.44
Enterprise Value/Revenue
4.03
Enterprise Value/EBITDA
13.77
Financial Highlights
Profitability and Income Statement
Profit Margin
17.53%
Return on Assets (ttm)
12.49%
Return on Equity (ttm)
36.36%
Revenue (ttm)
60.58B
Net Income Avi to Common (ttm)
10.62B
Diluted EPS (ttm)
1.95
Balance Sheet and Cash Flow
Total Cash (mrq)
8.81B
Total Debt/Equity (mrq)
110.04%
Levered Free Cash Flow (ttm)
8.13B
Research Analysis: RHHBY
View MoreCompany Insights: RHHBY
RHHBY does not have Company Insights
Research Reports: RHHBY
View MoreRoche: Obesity Pipeline Data Details Support Our Valuation and Leave Door Open for Differentiation
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
RatingPrice TargetArgus Quick Note: Weekly Stock List for 09/03/2024: Global Dividend Investing
Global stocks are gaining, if not at the pace of domestic equities. While the S&P 500 has risen 17% year to date, the EAFA index of large- and mid-cap stocks based in countries other than the U.S. and Canada has gained 9.5%. Over the past five years, the performance gap has been wider, with the S&P 500 advancing 94% compared to a 32% gain in EAFE. But the underperformance has given global stocks a valuation advantage, particularly in the area of dividends. Consider that the EAFE dividend yield of 2.9% is 170 basis points higher than the comparable S&P 500 dividend yield. We think global dividend stocks now offer opportunity, particularly given the endless speculation over the direction of interest rates in the U.S., which has created market-timing headaches for equity income investors, who have endured recent wide swings in prices for rate-sensitive equity in areas such as utilities, REITs and MLPs. In our view, investing in international income stocks is one way to increase portfolio diversification while reducing sensitivity to volatile U.S. interest rates. Investing in overseas stocks carries its own set of risks, including the impact of currency exchange and geopolitical turmoil. But there are also a number of positives in this asset class for U.S. investors, including a wide selection of companies that pay dividends, robust industry diversification, and, as we have mentioned, higher yields and lower valuations. Argus has recently boosted its global coverage, and recommends the following international dividend stocks, each of which has at least a long-term BUY rating from an Argus analyst. Note this list of approximately 25-30 companies offers exposure to eight of the 11 major industrial sectors. The list includes companies from 10 countries.
Lowering estimates for 2024 and 2025
Roche Holding AG operates through two segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment focuses on oncology, immunology, ophthalmology, infectious diseases and neuroscience, and the Diagnostics segment specializes in in vitro diagnostics. Headquartered in Basel, Switzerland, the company was founded by Fritz Hoffmann-La Roche in 1896. The company has approximately 103,605 employees. Roche has substantial market shares in oncology treatments and in vitro diagnostics, and is working to combine its expertise in these areas to develop personalized medicines based on the genetic characteristics of patients. In addition to organic growth, the company has a growth-by-acquisition strategy.
RatingPrice TargetThe major benchmarks were on the upside with the Nasdaq leading the way, up
The major benchmarks were on the upside with the Nasdaq leading the way, up more than 2%, amid a surge in semiconductor stocks. Investors await the 2 pm press release from the Federal Reserve on interest rates.